Halozyme Adds Biopharma Veteran Jim Daly to Board Amid Delivery Tech…

Event summary

Jim Daly, a biopharma executive with 30+ years of commercial leadership experience, rejoins Halozyme's Board of Directors on September 30, 2026.
Daly's background includes senior roles at Incyte, Amgen, and GlaxoSmithKline, with expertise in launching blockbuster therapies in respiratory, oncology, and immunology.
Halozyme is expanding its subcutaneous (SC) delivery technologies, including ENHANZE, Hypercon, and Aerocon, with Daly's commercial expertise seen as invaluable for growth.
Daly currently serves on the boards of Acadia Pharmaceuticals, Madrigal Pharmaceuticals, and Cytokinetics.

The big picture

Halozyme's appointment of Jim Daly reflects its strategic focus on scaling its subcutaneous drug delivery technologies. Daly's extensive experience in commercializing innovative therapies aligns with Halozyme's goal of expanding its portfolio of SC delivery solutions, which are licensed to leading pharmaceutical companies. This move underscores the importance of governance and commercial expertise in navigating the competitive biopharma landscape.

What we're watching

Commercial Execution: How Daly's track record in launching blockbuster therapies will translate to Halozyme's expansion of SC delivery technologies.
Strategic Partnerships: Whether Halozyme can leverage Daly's industry connections to secure additional high-profile partnerships for its delivery technologies.
Technology Adoption: The pace at which Hypercon and Aerocon technologies gain traction among biopharmaceutical partners, complementing ENHANZE.